MGF (Mechano Growth Factor): IGF-1 Splice Variant Research Profile
MGF — Mechano Growth Factor — is the IGF-1Ec splice variant produced locally in skeletal muscle within hours of mechanical loading or microtrauma. Unlike circulating IGF-1, MGF acts as a local first-responder: its primary role is satellite cell activation — the rate-limiting step in skeletal muscle repair and hypertrophy. Full research profile, mechanism, and literature review.
What is MGF?
Mechano Growth Factor (MGF) is an alternatively spliced isoform of the IGF-1 gene, specifically arising from exon 5 inclusion during mRNA processing in mechanically stressed muscle tissue. It was first characterized by Professor Geoffrey Goldspink and colleagues at University College London in the late 1990s and early 2000s, establishing a distinct local growth factor axis that operates independently of the systemic IGF-1 produced by the liver.
The critical structural distinction between MGF and mature IGF-1 is the C-terminal E-domain peptide — a unique sequence encoded by exon 6 that is absent from the systemic IGF-1Ea isoform. This E-domain peptide is responsible for MGF's satellite cell activating properties and binds a receptor distinct from the classical IGF-1 receptor, explaining why MGF and IGF-1 have different — and complementary — biological roles despite arising from the same gene.
MGF is classified as a paracrine/autocrine factor: it acts locally within the muscle tissue that produces it, not as a circulating hormone. This locality is both its primary advantage (targeted muscle repair without systemic hormone fluctuations) and its primary practical limitation (a plasma half-life of approximately 5–7 minutes in native form).
Mechanism of action
Phase 1 — Satellite cell activation (MGF). Within 2–3 hours of resistance training, eccentric loading, or direct muscle microtrauma, MGF mRNA expression peaks in the affected muscle fibers. MGF acts on quiescent satellite cells — the resident muscle stem cell population — triggering them to exit dormancy and begin proliferating. Critically, MGF inhibits premature terminal differentiation during this proliferative phase, preserving the satellite cell pool and ensuring an adequate supply of myogenic precursor cells for subsequent repair. Yang & Goldspink (2002) first demonstrated this biphasic role using in vitro myoblast models, showing that MGF's E-domain peptide specifically drives proliferation while suppressing the differentiation pathway that mature IGF-1 activates.
Phase 2 — Differentiation and fiber fusion (IGF-1Ea). As MGF expression declines over the 24–72 hours post-loading, systemic IGF-1Ea expression rises and is sustained. IGF-1Ea drives the satellite cells that MGF activated into terminal differentiation — they fuse with damaged fibers, donate myonuclei, and execute the structural repair and hypertrophy cascade. Hill & Goldspink (2003) confirmed this two-phase temporal sequence in rodent muscle, demonstrating that satellite cell markers (M-cadherin, MyoD) peak in alignment with the MGF pulse, not the subsequent IGF-1Ea rise.
Secondary mechanisms. Beyond satellite cell activation, MGF has demonstrated osteoblast proliferation via MAPK-ERK1/2 pathway activation in preclinical models, suggesting roles in bone tissue adaptation to mechanical load. Cardioprotective anti-apoptotic signaling in cardiac muscle under ischemic conditions has also been reported. A 2019 study demonstrated that MGF attenuates mechanical overload-induced chondrocyte apoptosis, with potential relevance to cartilage preservation under high compressive loading. These secondary mechanisms are based on preclinical in vitro and animal data and remain investigational.
Quick specifications
| Parameter | Value |
|---|---|
| Classification | IGF-1 gene splice variant (IGF-1Ec isoform) |
| Origin | Locally produced in skeletal muscle in response to mechanical load |
| Key structural feature | Unique C-terminal E-domain peptide (exon 6); absent in IGF-1Ea |
| Primary receptor | Distinct from classical IGF-1R; E-domain binds separate receptor |
| Native half-life | ~5–7 minutes (rapidly degraded in plasma) |
| Administration (research) | Intramuscular — injected into the worked muscle group post-training |
| PEGylated form | PEG-MGF — extended half-life version; see comparison below |
| Human clinical trials | None to date; evidence base is preclinical and in vitro |
Age-related blunting — why recovery slows
One of the most clinically significant findings in MGF research is the age-dependent decline in its exercise-induced expression. Hameed et al. (2003) demonstrated that elderly subjects show substantially reduced MGF mRNA expression in quadriceps muscle biopsies following a standardized bout of resistance exercise — with young subjects exhibiting a pronounced MGF spike that was largely absent or blunted in their older counterparts, despite equivalent mechanical loading.
Subsequent work confirmed this pattern across exercise modalities: Welle et al. (2008, PMID 18067523) found that eccentric cycling produced robust MGF induction in young subjects (aged 20–27) but minimal response in elderly subjects (aged 67–75), with IGF-1Ea expression comparatively preserved in both groups. This differential — blunted MGF, preserved IGF-1Ea — disrupts the two-phase repair sequence: the satellite cell activation signal fails to fire, even though the downstream differentiation machinery remains intact.
The practical implication: age-related muscle loss (sarcopenia) may be partially driven not by failure of the systemic IGF-1 axis but by failure of the local MGF pulse to adequately activate satellite cells following mechanical stimulus. This positions MGF as a research target for understanding — and potentially addressing — the satellite cell activation deficit in aging muscle.
MGF vs. PEG-MGF
| Feature | MGF (native) | PEG-MGF |
|---|---|---|
| Half-life | ~5–7 minutes | Extended (days; vendor-reported, not published human data) |
| Action | Local — acts at injection site muscle | Systemic circulation; less site-specific |
| Research model | Mimics acute, transient post-exercise MGF pulse | Models sustained, circulating MGF exposure |
| Administration | Intramuscular, immediately post-training | Subcutaneous or intramuscular |
| Evidence base | Yang & Goldspink (2002); Hill & Goldspink (2003); Goldspink (2005) | Limited; primarily preclinical |
| Key caveat | 5-minute window limits systemic delivery; must be injected IM into worked muscle | PEGylation may alter receptor interaction; extended half-life claim is not human-validated |
The choice between MGF and PEG-MGF as research tools depends on the question being studied. MGF best models the physiological acute local pulse — relevant for understanding the native repair mechanism and satellite cell biology. PEG-MGF allows researchers to study the effects of sustained MGF-like exposure, though the PEGylation modification introduces uncertainty about whether the extended E-domain peptide retains identical receptor binding properties. For the unmodified research compound, see the MGF database entry; for PEGylated, see the PEG-MGF database entry.
Research dosing context
The following reflects dosing parameters referenced in the preclinical literature and research community. For educational purposes only — not medical advice. No human clinical trial dosing data exists for MGF.
| Parameter | Research Reference Range |
|---|---|
| Dose range | 100–200 mcg per injection (preclinical reference) |
| Frequency | Post-training, injected into the worked muscle group |
| Timing | Immediately post-exercise (within the acute MGF expression window) |
| Route | Intramuscular (IM) — subcutaneous delivery is not consistent with the local mechanism |
| Common research combination | IGF-1 LR3 (phase 2 — differentiation support); see also PEG-MGF for extended action |
Reconstitution: Reconstitute with bacteriostatic water per vial specifications. Store reconstituted peptide refrigerated at 2–8°C. Use within 28 days. Do not freeze after reconstitution.
Research references
- Yang SY, Goldspink G. (2002). Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Letters. 522(1–3):156–160. PubMed
- Hill M, Goldspink G. (2003). Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 549(Pt 2):409–418. PubMed
- Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD. (2003). Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol. 547(Pt 1):247–254. PubMed
- Goldspink G. (2005). Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 20:232–238. PubMed
- Welle S, Bhatt K, Shah B, Thornton C. (2008). Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62 and 22 year old men. Exp Gerontol. 43(3):179–184. PubMed (eccentric exercise, IGF splice variant expression, young vs elderly)